Chuan Hao

Chuan Hao


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2024 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
YXYanbo Xing
Yanbo Xing
QGQiang Guo
Qiang Guo
CWCong Wang
Cong Wang
HSHaoying Shi
Haoying Shi
JZJiarui Zheng
Jiarui Zheng
CHChuan Hao
Chuan Hao
Donor-derived cell-free DNA (dd-cfDNA) has emerged as a promising biomarker for detecting graft rejection. This study aimed to evaluate the diagnostic accuracy and clinical value of applying it to kidney transplant rejection. Relevant literature on dd-cfDNA diagnostics in kidney transplant rejection was reviewed from PubMed, Embase, Cochrane Library, and Web of Science databases up to 2023. Data and study characteristics were extracted independently by two researchers, and disagreements were resolved through discussion. Diagnostic accuracy data for any rejection (AR) and antibody-mediated rejection (ABMR) were analyzed separately. Potential heterogeneity was analyzed by subgroup analysis or meta-regression. Funnel plots were used to clarify the presence or absence of publication bias. Nine publications provided data on dd-cfDNA accuracy in diagnosing patients with AR. The pooled sensitivity, specificity, and the area under the receiver operating characteristic (AUROC) curve with 95% confidence intervals (CI) were 0.59 (95% CI, 0.48-0.69), 0.83 (95% CI, 0.76-0.88), and 0.80 (95% CI, 0.76-0.83), respectively. Additionally, 12 studies focused on the diagnostic accuracy of dd-cfDNA for ABMR, showing pooled sensitivity, specificity, and the AUROC curve with 95% CI of 0.81 (95% CI, 0.72–0.88), 0.80 (95% CI, 0.73–0.86), and 0.87 (95% CI, 0.84-0.90), respectively. Study type, age group, and sample size contributed to heterogeneity. In summary, our findings indicate that while plasma dd-cfDNA accuracy in diagnosing patients with AR is limited by significant heterogeneity, it is a valuable biomarker for diagnosing ABMR.

18 April 2023 in Renal Failure
Verified
Journal Article
Open access
JBJiang Bai
Jiang Bai
TZTianxiang Zhang
Tianxiang Zhang
YWYan Wang
Yan Wang
JCJiajing Cao
Jiajing Cao
ZDZihui Duan
Zihui Duan
QGQiang Guo
Qiang Guo
To systematically review the incidence and risk factors for recurrent FSGS after kidney transplantation.We searched PubMed, Embase, Medline, Web of Science, the Cochrane Library, CNKI, CBMdisc, Wan...

6 January 2023 in Frontiers in Surgery
Verified
Journal Article
Open access
XZXiaoyu Zi
Xiaoyu Zi
XZXi Zhang
Xi Zhang
CHChuan Hao
Chuan Hao
ZWZhenxing Wang
Zhenxing Wang
Hyperuricemia (HUA) is a common complication after renal transplantation. Currently, there is no uniform consensus on factors which increase the risk for and treatment of HUA in renal transplant recipients. The purpose of this review is to summarize current and proposed risk factors and strategies to manage HUA after renal transplantation in order to assist renal function protection and prolong graft survival time.

16 November 2023 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
XZXingming Zhao
Xingming Zhao
YXYanbo Xing
Yanbo Xing
XZXi Zhang
Xi Zhang
QGQiang Guo
Qiang Guo
CLChengyong Li
Chengyong Li
CHChuan Hao
Chuan Hao
Sexual function after urethroplasty may be a concern for patients, but there are still some controversies regarding the consequences of nontransecting bulbar urethroplasty (ntBU) in terms of erectile dysfunction (ED). This meta-analysis aimed to compare the efficacy and safety of ntBU with that of transecting bulbar urethroplasty (tBU). The PubMed, Web of Science, Cochrane, and Embase databases were searched and reviewed up to October 31, 2022. Quality evaluation was performed using the Newcastle-Ottawa scale system and Cochrane tools for the nonrandomized and randomized studies, respectively. Baseline characteristics, preoperative information, and postoperative outcomes were collected. Outcomes included success rate, ED, overall complication, and maximum urinary flow. Thirteen studies comprising 1683 patients met the inclusion criteria, with 596 and 1087 patients undergoing ntBU and tBU, respectively. The results revealed that compared with the tBU group, the patients who underwent ntBU had a significantly lower incidence of ED, while there were no significant differences in the other perioperative outcomes. In subgroup analysis, the nontransecting anastomotic urethroplasty group had a lower incidence of ED than excision and primary anastomosis, and other perioperative outcomes were similar between the 2 groups. The results of the study may help clinicians choose procedures that protect sexual function in the treatment of urethral stricture. The strength of this study is that it is, to our knowledge, the first meta-analysis to evaluate the efficacy and safety of ntBU. A limitation is that most of the included studies were retrospective cohort studies. ntBU preserves the high efficacy of its transecting counterpart while reducing postoperative ED.

13 August 2024 in Sexual Medicine
Verified
Journal Article
Open access
PDF file
XZXingming Zhao
Xingming Zhao
QGQiang Guo
Qiang Guo
XZXi Zhang
Xi Zhang
QXQi Xing
Qi Xing
SRSheng Ren
Sheng Ren
JWJingqi Wang
Jingqi Wang
The urinary and sexual outcomes after urethroplasty may be a concern for patients, but there are still some controversies regarding the consequences of buccal mucosal graft urethroplasty (BMG) in terms of erectile dysfunction (ED). This meta-analysis aimed to compare urinary and sexual outcomes of BMG and end-to-end urethroplasty (EE). The PubMed, Web of Science, Cochrane, and Embase databases were searched until February 31, 2023. Data extraction and quality assessment were performed by 2 designated researchers. Dichotomous data were analyzed as odds ratios with 95% confidence intervals (CIs). Heterogeneity across studies was assessed by the I2 quantification, and publication bias using Begg’s and Egger’s tests. Meta-analysis was performed using RevMan software. Outcomes included stricture recurrence, ED, penile complications, and voiding symptoms. Eighteen studies, including 1648 participants, were included in our meta-analysis. The meta-analysis revealed that there was no significant difference in stricture recurrence (OR = 0.74; 95% CI, 0.48–1.13; P = .17) and voiding symptoms (OR = 1.12; 95% CI, 0.32–3.88; P = .86) between the BMG group and the EE group. BMG was associated with lower risk of penile complications (OR = 0.40; 95% CI, 0.24–0.69; P = .001) and ED (OR = 0.53, 95% CI, 0.32–0.90, P = .02). The study may help clinicians choose procedures that achieve better recovery of the urological and sexual function in the treatment of urethral stricture. This meta-analysis is the first to evaluate the urinary and sexual outcomes of BMG vs EE. A limitation is that most of the included studies were retrospective cohort studies. BMG is as effective as EE in the treatment of bulbar urethral stricture, but BMG has fewer complications and ED than EE.

21 February 2024 in International Journal of Urology
Verified
Journal Article
Closed access
YXYanbo Xing
Yanbo Xing
HSHaoying Shi
Haoying Shi
QGQiang Guo
Qiang Guo
CWCong Wang
Cong Wang
CLChengyong Li
Chengyong Li
CHChuan Hao
Chuan Hao